560 related articles for article (PubMed ID: 15547182)
1. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas.
Feng WH; Cohen JI; Fischer S; Li L; Sneller M; Goldbach-Mansky R; Raab-Traub N; Delecluse HJ; Kenney SC
J Natl Cancer Inst; 2004 Nov; 96(22):1691-702. PubMed ID: 15547182
[TBL] [Abstract][Full Text] [Related]
2. Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: potential switches in latent gene expression due to coinfection.
Callahan J; Pai S; Cotter M; Robertson ES
Virology; 1999 Sep; 262(1):18-30. PubMed ID: 10489337
[TBL] [Abstract][Full Text] [Related]
3. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo.
Westphal EM; Mauser A; Swenson J; Davis MG; Talarico CL; Kenney SC
Cancer Res; 1999 Apr; 59(7):1485-91. PubMed ID: 10197618
[TBL] [Abstract][Full Text] [Related]
4. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection.
Miyazaki T; Fujimaki K; Shirasugi Y; Yoshiba F; Ohsaka M; Miyazaki K; Yamazaki E; Sakai R; Tamaru J; Kishi K; Kanamori H; Higashihara M; Hotta T; Ishigatsubo Y
Am J Hematol; 2007 Dec; 82(12):1106-9. PubMed ID: 17654684
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjögren's syndrome: case series.
Dawson TM; Starkebaum G; Wood BL; Willkens RF; Gown AM
J Rheumatol; 2001 Jan; 28(1):47-53. PubMed ID: 11196542
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis.
Balandraud N; Guis S; Meynard JB; Auger I; Roudier J; Roudier C
Arthritis Rheum; 2007 Jun; 57(5):762-7. PubMed ID: 17530675
[TBL] [Abstract][Full Text] [Related]
7. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
8. Lymphomas in patients with connective tissue disease. Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate.
Menke DM; Griesser H; Moder KG; Tefferi A; Luthra HS; Cohen MD; Colon-Otero G; Lloyd RV
Am J Clin Pathol; 2000 Feb; 113(2):212-8. PubMed ID: 10664623
[TBL] [Abstract][Full Text] [Related]
9. EBV-associated diffuse large B-cell lymphoma in a psoriatic treated with methotrexate.
Hsiao SC; Ichinohasama R; Lin SH; Liao YL; Chang ST; Cho CY; Chuang SS
Pathol Res Pract; 2009; 205(1):43-9. PubMed ID: 18951733
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis.
Paul C; Le Tourneau A; Cayuela JM; Devidas A; Robert C; Molinié V; Dubertret L
Arch Dermatol; 1997 Jul; 133(7):867-71. PubMed ID: 9236525
[TBL] [Abstract][Full Text] [Related]
11. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
12. Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin.
Hsu CH; Hergenhahn M; Chuang SE; Yeh PY; Wu TC; Gao M; Cheng AL
Anticancer Res; 2002; 22(6C):4065-71. PubMed ID: 12553034
[TBL] [Abstract][Full Text] [Related]
13. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression.
Feng WH; Kenney SC
Cancer Res; 2006 Sep; 66(17):8762-9. PubMed ID: 16951192
[TBL] [Abstract][Full Text] [Related]
14. Lytic cycle switches of oncogenic human gammaherpesviruses.
Miller G; El-Guindy A; Countryman J; Ye J; Gradoville L
Adv Cancer Res; 2007; 97():81-109. PubMed ID: 17419942
[TBL] [Abstract][Full Text] [Related]
15. A molecular link between malaria and Epstein-Barr virus reactivation.
Chêne A; Donati D; Guerreiro-Cacais AO; Levitsky V; Chen Q; Falk KI; Orem J; Kironde F; Wahlgren M; Bejarano MT
PLoS Pathog; 2007 Jun; 3(6):e80. PubMed ID: 17559303
[TBL] [Abstract][Full Text] [Related]
16. Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product.
Adamson AL; Kenney SC
Virology; 1998 Nov; 251(1):187-97. PubMed ID: 9813214
[TBL] [Abstract][Full Text] [Related]
17. Nuclear factor-Y and Epstein Barr virus in nasopharyngeal cancer.
Chia MC; Leung A; Krushel T; Alajez NM; Lo KW; Busson P; Klamut HJ; Bastianutto C; Liu FF
Clin Cancer Res; 2008 Feb; 14(4):984-94. PubMed ID: 18281530
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis. Role of Epstein-Barr virus infection.
Lioté F; Pertuiset E; Cochand-Priollet B; D'Agay MF; Dombret H; Numéric P; D'Anglejan G; Kuntz D
J Rheumatol; 1995 Jun; 22(6):1174-8. PubMed ID: 7674250
[TBL] [Abstract][Full Text] [Related]
19. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.
Hoshida Y; Xu JX; Fujita S; Nakamichi I; Ikeda J; Tomita Y; Nakatsuka S; Tamaru J; Iizuka A; Takeuchi T; Aozasa K
J Rheumatol; 2007 Feb; 34(2):322-31. PubMed ID: 17117491
[TBL] [Abstract][Full Text] [Related]
20. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
